{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:17:26Z","timestamp":1777781846809,"version":"3.51.4"},"reference-count":71,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["L40DA056968"],"award-info":[{"award-number":["L40DA056968"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Atten Disord"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>Assess prevalence and correlates of cannabis use in adults with attention-deficit\/hyperactivity disorder (ADHD) and explore its impact on comorbidities, symptoms, and side effects of prescription stimulants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An anonymous online survey (April to July 2023) was emailed to 9,274 potential adult participants with a documented ADHD diagnosis, based on ICD-10 codes in the electronic medical record, which was secondarily verified by self-report. A total of 900 participants completed the survey. The 46-item survey covered demographics, medical history, prescription stimulant use, cannabis use, and its impact on ADHD symptoms and prescribed stimulant side effects, prescription stimulant misuse, cannabis use disorder, and health-related quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In this large sample of adults diagnosed with ADHD, 75% reported ever using cannabis, with 41% reporting prior 30-day use. Groups of cannabis users were categorized into three groups; (1) no recent use (including never;\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009458); (2) non-daily use (&lt;30\u2009days in past month;\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009256); and (3) daily use (\u226530\u2009days in past month;\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009112). Compared to non-daily cannabis users, daily cannabis users showed comparable rates of prescription stimulant misuse (29% vs. 37%, OR\u2009=\u20091.39, 95% CI [0.87, 2.23],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.166), and substance use disorder diagnoses (2% vs. 4%, OR\u2009=\u20091.54, 95% CI [0.43, 5.58],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.508), but higher rates of cannabis use disorder (38% vs. 62%, OR\u2009=\u20092.67, 95% CI [1.69, 4.22],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001). Daily cannabis users were more likely to report fair or poor general health compared to non-daily cannabis users (24% vs. 11%, OR\u2009=\u20092.58, 95% CI [1.44, 4.64],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.001). Daily cannabis users were more likely to report a comorbid diagnosis of anxiety (70% vs. 48%, OR\u2009=\u20092.55, 95% CI [1.59, 4.10],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001), depression (54% vs. 35%, OR\u2009=\u20092.24, 95% CI [1.42, 3.53],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001), bipolar disorder (15% vs. 5%, OR\u2009=\u20093.345, 95% CI [1.56, 7.15],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.002), and post-traumatic stress disorder (PTSD) (30% vs. 14%, OR\u2009=\u20092.752, 95% CI [1.61, 4.71],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001), compared to non-daily cannabis users. Among participants who ever used cannabis, 278 (42%) reported they had used cannabis to manage their ADHD symptoms. Compared to non-daily cannabis users, daily cannabis users were significantly more likely to report that cannabis use improved ADHD symptoms of mental frustration (OR\u2009=\u20092.39, 95% CI [1.36, 4.19],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.002) and impulsivity (OR\u2009=\u20091.69, 95% CI [1.07, 2.69],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.026). Daily cannabis users were more likely to report that cannabis use worsened ADHD symptoms of inattention (OR\u2009=\u2009.59, 95% CI [0.36, 0.98],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.043) compared to non-daily cannabis users. Participants reported mixed effects of cannabis use on anxiety: 156 noted improvements, while 34 reported worsening.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this sample of adults diagnosed with ADHD, cannabis use was prevalent, with daily users showing higher rates of cannabis use disorder and co-morbid psychiatric diagnoses compared to non-daily users, highlighting the need for clinicians to screen for cannabis use disorder and psychiatric comorbidities. Cannabis users reported mixed effects of cannabis on ADHD symptoms and anxiety. Further research is warranted to understand the complex relationship between cannabis use, ADHD symptoms, and mental health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10870547251364575","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:48:41Z","timestamp":1756385321000},"page":"407-422","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cannabis Use in a Community-Based Sample of Adults Diagnosed With ADHD: Prevalence, Impact on Symptoms, and Stimulant Side Effects"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9726-3602","authenticated-orcid":false,"given":"Jennie E.","family":"Ryan","sequence":"first","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Herens","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Fruchtman","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-3468","authenticated-orcid":false,"given":"Philip","family":"Veliz","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin L.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Worster","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318192e4a0"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0304"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-022-00135-y"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900002406"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Blanco C. Hasin D. S. Wall M. M. Fl\u00f3rez-Salamanca L. Hoertel N. Wang S. Kerridge B. T. Olfson M. (2016). Cannabis use and risk of psychiatric disorders: Prospective evidence from a US national longitudinal study. JAMA Psychiatry 73(4) 388\u2013395. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.3229","DOI":"10.1001\/jamapsychiatry.2015.3229"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Bonn-Miller M. O. Boden M. T. Bucossi M. M. Babson K. A. (2014). Self-reported cannabis use characteristics patterns and helpfulness among medical cannabis users. American Journal of Drug and Alcohol Abuse 40(1) 23\u201330. https:\/\/doi.org\/10.3109\/00952990.2013.821477","DOI":"10.3109\/00952990.2013.821477"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0022"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Broyd S. J. van Hell H. H. Beale C. Y\u00fccel M. Solowij N. (2016 Apr 1). Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biological Psychiatry 79(7) 557\u2013567. https:\/\/doi.org\/10.1016\/j.biopsych.2015.12.002","DOI":"10.1016\/j.biopsych.2015.12.002"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1027\/2151-2604\/a000394"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Callovini T. Janiri D. Segatori D. Mastroeni G. Kotzalidis G. D. Di Nicola M. Sani G. (2024). Examining the myth of prescribed stimulant misuse among individuals with attention-deficit\/hyperactivity disorder: A systematic review. Pharmaceuticals 17(8) 1076. https:\/\/www.mdpi.com\/1424-8247\/17\/8\/1076","DOI":"10.3390\/ph17081076"},{"issue":"16","key":"e_1_3_3_12_1","first-page":"326","article-title":"Self-reported frequent mental distress among adults\u2013United States, 1993-1996","volume":"47","author":"Center for Disease Control and Prevention","year":"1998","unstructured":"Center for Disease Control and Prevention. (1998). Self-reported frequent mental distress among adults\u2013United States, 1993-1996. MMWR. Morbidity and Mortality Weekly Report, 47(16), 326\u2013331.","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"e_1_3_3_13_1","unstructured":"Center for Disease Control and Prevention. (2001). Measuring healthy days: Population assessment of health-related quality of life. Retrieved June 24 2025 from https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/hrqol\/hrqol14_measure.htm"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Chai G. Governale L. McMahon A. W. Trinidad J. P. Staffa J. Murphy D. (2012). Trends of outpatient prescription drug utilization in US children 2002-2010. Pediatrics 130(1) 23\u201331. https:\/\/doi.org\/10.1542\/peds.2011-2879","DOI":"10.1542\/peds.2011-2879"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3928\/00485713-20230911-04"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNP.0000000000000617"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Choi W. S. Woo Y. S. Wang S. M. Lim H. K. Bahk W. M. (2022). The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: A systematic literature review. PloS One 17(11) e0277175. https:\/\/doi.org\/10.1371\/journal.pone.0277175","DOI":"10.1371\/journal.pone.0277175"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17091048"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.05.008"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/00131640021970934"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Cortese S. (2020 Sep 10). Pharmacologic treatment of attention deficit-hyperactivity disorder. New England Journal of Medicine 383(11) 1050\u20131056. https:\/\/doi.org\/10.1056\/NEJMra1917069","DOI":"10.1056\/NEJMra1917069"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Cortese S. Adamo N. Del Giovane C. Mohr-Jensen C. Hayes A. J. Carucci S. Atkinson L. Z. Tessari L. Banaschewski T. Coghill D. Hollis C. Simonoff E. Zuddas A. Barbui C. Purgato M. Steinhausen H. C. Shokraneh F. Xia J. Cipriani A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children adolescents and adults: A systematic review and network meta-analysis. Lancet Psychiatry 5(9) 727\u2013738. https:\/\/doi.org\/10.1016\/s2215-0366(18)30269-4","DOI":"10.1016\/S2215-0366(18)30269-4"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Cranford J. A. Arnedt J. T. Conroy D. A. Bohnert K. M. Bourque C. Blow F. C. Ilgen M. (2017). Prevalence and correlates of sleep-related problems in adults receiving medical cannabis for chronic pain. Drug and Alcohol Dependence 180 227\u2013233. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.08.017","DOI":"10.1016\/j.drugalcdep.2017.08.017"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1169-0"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2019.11.001"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.04.054"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2019.102207"},{"key":"e_1_3_3_28_1","volume-title":"Stimulant prescription trends in the United States from 2012-2022","author":"Drug Enforcement Agency (DEA) and IQVIA Government Solutions, Inc","year":"2023","unstructured":"Drug Enforcement Agency (DEA) and IQVIA Government Solutions, Inc. (2023). Stimulant prescription trends in the United States from 2012-2022. Administration DEA."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1353\/rhe.2017.0003"},{"key":"e_1_3_3_30_1","doi-asserted-by":"crossref","unstructured":"Francisco A. P. Lethbridge G. Patterson B. Goldman Bergmann C. Van Ameringen M. (2023). Cannabis use in attention \u2013 deficit\/hyperactivity disorder (ADHD): A scoping review. Journal of Psychiatric Research 157 239\u2013256. https:\/\/doi.org\/10.1016\/j.jpsychires.2022.11.029","DOI":"10.1016\/j.jpsychires.2022.11.029"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.567256"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.092940"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"Gujska J. H. Silczuk A. Madejek R. Szulc A. (2023). Exploring the link between attention-deficit yyperactivity disorder and cannabis use disorders: A review. Medical Science Monitor 29 e939749. https:\/\/doi.org\/10.12659\/msm.939749","DOI":"10.12659\/MSM.939749"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107867"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050849"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","unstructured":"Hart C. L. van Gorp W. Haney M. Foltin R. W. Fischman M. W. (2001). Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25(5) 757\u2013765. https:\/\/doi.org\/10.1016\/s0893-133x(01)00273-1","DOI":"10.1016\/S0893-133X(01)00273-1"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2015.1018545"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Hasin D. S. Shmulewitz D. Sarvet A. L. (2019). Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: A narrative review and new findings. American Journal of Drug and Alcohol Abuse 45(6) 623\u2013643. https:\/\/doi.org\/10.1080\/00952990.2019.1569668","DOI":"10.1080\/00952990.2019.1569668"},{"key":"e_1_3_3_39_1","doi-asserted-by":"crossref","unstructured":"Hasin D. Walsh C. (2021). Cannabis Use cannabis use disorder and comorbid psychiatric illness: A narrative review. Journal of Clinical Medicine 10(1) 15. https:\/\/www.mdpi.com\/2077-0383\/10\/1\/15","DOI":"10.3390\/jcm10010015"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717001222"},{"key":"e_1_3_3_41_1","volume-title":"Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD practice guidelines","author":"Jain U.","year":"2006","unstructured":"Jain U., Hechtman L., Quinn D., Turgay A., Yaremko J., Mutch C. (2006). Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD practice guidelines. CADDRA."},{"key":"e_1_3_3_42_1","doi-asserted-by":"crossref","unstructured":"Katzman M. A. Bilkey T. S. Chokka P. R. Fallu A. Klassen L. J. (2017). Adult ADHD and comorbid disorders: Clinical implications of a dimensional approach. BMC Psychiatry 17(1) 302. https:\/\/doi.org\/10.1186\/s12888-017-1463-3","DOI":"10.1186\/s12888-017-1463-3"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291704002892"},{"key":"e_1_3_3_44_1","doi-asserted-by":"crossref","unstructured":"Kessler R. C. Adler L. Barkley R. Biederman J. Conners C. K. Demler O. Faraone S. V. Greenhill L. L. Howes M. J. Secnik K. Spencer T. Ustun T. B. Walters E. E. Zaslavsky A. M. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry 163(4) 716\u2013723. https:\/\/doi.org\/10.1176\/ajp.2006.163.4.716","DOI":"10.1176\/ajp.2006.163.4.716"},{"key":"e_1_3_3_45_1","doi-asserted-by":"crossref","unstructured":"Klein R. G. Mannuzza S. Olazagasti M. A. R. Roizen E. Hutchison J. A. Lashua E. C. Castellanos F. X. (2012). Clinical and functional outcome of childhood attention-deficit\/hyperactivity disorder 33 years later. Archives of General Psychiatry 69(12) 1295\u20131303. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2012.271","DOI":"10.1001\/archgenpsychiatry.2012.271"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-019-0013-x"},{"key":"e_1_3_3_47_1","doi-asserted-by":"crossref","unstructured":"Landes S. D. London A. S. (2021). Self-reported ADHD and adult health in the United States. Journal of Attention Disorders 25(1) 3\u201313. https:\/\/doi.org\/10.1177\/1087054718757648","DOI":"10.1177\/1087054718757648"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2011.01.006"},{"key":"e_1_3_3_49_1","doi-asserted-by":"crossref","unstructured":"Leung J. Chan G. C. K. Hides L. Hall W. D. (2020). What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addictive Behaviors 109 Article 106479. https:\/\/doi.org\/10.1016\/j.addbeh.2020.106479","DOI":"10.1016\/j.addbeh.2020.106479"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2013.841251"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2016.06.021"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054719855689"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/147078530805000107"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/104012371002200309"},{"key":"e_1_3_3_55_1","doi-asserted-by":"crossref","unstructured":"McCabe S. E. Schulenberg J. E. Wilens T. E. Schepis T. S. McCabe V. V. Veliz P. T. (2023). Prescription stimulant medical and nonmedical use among US secondary school students 2005 to 2020. JAMA Network Open 6(4) e238707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.8707","DOI":"10.1001\/jamanetworkopen.2023.8707"},{"key":"e_1_3_3_56_1","doi-asserted-by":"crossref","unstructured":"Mitchell J. T. Sweitzer M. M. Tunno A. M. Kollins S. H. McClernon F. J. (2016). \u201cI use weed for my ADHD\u201d: A qualitative analysis of online forum discussions on cannabis use and ADHD. PloS ONE 11(5) e0156614. https:\/\/doi.org\/10.1371\/journal.pone.0156614","DOI":"10.1371\/journal.pone.0156614"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054716685842"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054716640109"},{"key":"e_1_3_3_59_1","doi-asserted-by":"crossref","unstructured":"Olfson M. Blanco C. Wang S. Greenhill L. L. (2013). Trends in office-based treatment of adults with stimulants in the United States. Journal of Clinical Psychiatry 74(1) 43\u201350. https:\/\/doi.org\/10.4088\/JCP.12m07975","DOI":"10.4088\/JCP.12m07975"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108092393"},{"key":"e_1_3_3_61_1","doi-asserted-by":"crossref","unstructured":"Ryan J. E. Fruchtman M. Sparr-Jaswa A. Knehans A. Worster B. (2024). Attention deficit hyperactivity disorder cannabis use and the endocannabinoid System: A scoping review. Developmental Psychobiology 66(7) e22540. https:\/\/doi.org\/10.1002\/dev.22540","DOI":"10.1002\/dev.22540"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02518-2"},{"key":"e_1_3_3_63_1","doi-asserted-by":"crossref","unstructured":"Slabaugh S. L. Shah M. Zack M. Happe L. Cordier T. Havens E. Davidson E. Miao M. Prewitt T. Jia H. (2017). Leveraging Health-Related Quality of Life in population health management: The case for Healthy Days. Population Health Management 20(1) 13\u201322. https:\/\/doi.org\/10.1089\/pop.2015.0162","DOI":"10.1089\/pop.2015.0162"},{"key":"e_1_3_3_64_1","doi-asserted-by":"crossref","unstructured":"Sobanski E. Br\u00fcggemann D. Alm B. Kern S. Deschner M. Schubert T. Philipsen A. Rietschel M. (2007). Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit\/hyperactivity disorder (ADHD). European Archives of Psychiatry and Clinical Neuroscience 257(7) 371\u2013377. https:\/\/doi.org\/10.1007\/s00406-007-0712-8","DOI":"10.1007\/s00406-007-0712-8"},{"key":"e_1_3_3_65_1","doi-asserted-by":"crossref","unstructured":"Stueber A. Cuttler C. (2022). Self-reported effects of cannabis on ADHD symptoms ADHD medication side effects and ADHD-related executive dysfunction. Journal of Attention Disorders 26(6) 942\u2013955. https:\/\/doi.org\/10.1177\/10870547211050949","DOI":"10.1177\/10870547211050949"},{"key":"e_1_3_3_66_1","unstructured":"Substance Abuse and Mental Health Services Administration (SAMSHA). (2021). 2020 National Survey on Drug Use and Health (NSDUH): Methodological summary and definitions. Rockville MD."},{"key":"e_1_3_3_67_1","doi-asserted-by":"crossref","unstructured":"Torgersen T. Gjervan B. Rasmussen K. Vaaler A. Nordahl H. M. (2013). Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD. Atten Defic Hyperact Disord 5(1) 59\u201367. https:\/\/doi.org\/10.1007\/s12402-012-0094-2","DOI":"10.1007\/s12402-012-0094-2"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4395"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1017\/S109285290000242X"},{"key":"e_1_3_3_70_1","doi-asserted-by":"crossref","unstructured":"Wilens T. E. (2006). Attention deficit hyperactivity disorder and substance use disorders. The American Journal of Psychiatry 163(12) 2059\u20132063. https:\/\/doi.org\/http:\/\/dx.doi.org\/10.1176\/appi.ajp.163.12.2059","DOI":"10.1176\/ajp.2006.163.12.2059"},{"key":"e_1_3_3_71_1","doi-asserted-by":"crossref","unstructured":"Willcutt E. G. (2012). The prevalence of DSM-IV attention-deficit\/hyperactivity disorder: A meta-analytic review. Neurotherapeutics 9(3) 490\u2013499. https:\/\/doi.org\/10.1007\/s13311-012-0135-8","DOI":"10.1007\/s13311-012-0135-8"},{"issue":"4","key":"e_1_3_3_72_1","first-page":"1","article-title":"Health-related quality of life surveillance\u2014United States, 1993\u20132002","volume":"54","author":"Zahran H. S.","year":"2005","unstructured":"Zahran H. S., Kobau R., Moriarty D. G., Zack M. M., Holt J., Donehoo R. (2005). Health-related quality of life surveillance\u2014United States, 1993\u20132002. Morbidity and Mortality Weekly Report: Surveillance Summaries, 54(4), 1\u201335.","journal-title":"Morbidity and Mortality Weekly Report: Surveillance Summaries"}],"container-title":["Journal of Attention Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547251364575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10870547251364575","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547251364575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:30:36Z","timestamp":1777491036000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10870547251364575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/10870547251364575"],"URL":"https:\/\/doi.org\/10.1177\/10870547251364575","relation":{},"ISSN":["1087-0547","1557-1246"],"issn-type":[{"value":"1087-0547","type":"print"},{"value":"1557-1246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}